Blue Lake Biotechnology is re-inventing vaccines with a next generation intranasal vaccine vector. Our plug-and-play platform produces vaccines that generate a full spectrum of immune responses to produce superior immunity. We have a robust clinic-stage pipeline of best-in-class vaccines. Our lead vaccine candidates demonstrated robust cellular immunity in Phase 1 and early evidence of superior clinical efficacy over mRNA vaccines, and are now in Phase 2 trials.